Inflammation‐Controlled Anti‐Inflammatory Hydrogels

Abstract

While autoregulative adaptation is a common feature of living tissues, only a few feedback‐controlled adaptive biomaterials are available so far. This paper herein reports a new polymer hydrogel platform designed to release anti‐inflammatory molecules in response to the inflammatory activation of human blood. In this system, anti‐inflammatory peptide drugs, targeting either the complement cascade, a complement receptor, or cyclophilin A, are conjugated to the hydrogel by a peptide sequence that is cleaved by elastase released from activated granulocytes. As a proof of concept, the adaptive drug delivery from the gel triggered by activated granulocytes and the effect of the released drug on the respective inflammatory pathways are demonstrated. Adjusting the gel functionalization degree is shown to allow for tuning the drug release profiles to effective doses within a micromolar range. Feedback‐controlled delivery of covalently conjugated drugs from a hydrogel matrix is concluded to provide valuable safety features suitable to equip medical devices with highly active anti‐inflammatory agents without suppressing the general immunosurveillance.

Allicin-Loaded Intelligent Hydrogel Coating Improving Vascular Implant Performance

“…It may be a tendency that the next generation of stents could take the oxidative stress microenvironment by intelligent features that respond to the inflammatory and oxidative stress stimuli with the release of drugs for precise treatment, and simultaneously modulate the oxidative environment to avoid complications of stenting and promote vascular tissue repair . Recently, the application of hydrogel coatings on stent surfaces has started to gain attention. , Compared with conventional coatings, hydrogels have the advantages of high drug loading, easy-to-build intelligent responses, three-dimensional structure that facilitates cell growth, and mechanical states closer to healthy vascular intima . This inspires us that it will be of theoretical importance to construct a new smart hydrogel coating with high binding to vascular stents that respond to ROS for drug release …”

“…8 Recently, the application of hydrogel coatings on stent surfaces has started to gain attention. 9,10 Compared with conventional coatings, hydrogels have the advantages of high drug loading, easy-to-build intelligent responses, three-dimensional structure that facilitates cell growth, and mechanical states closer to healthy vascular intima. 11 This inspires us that it will be of theoretical importance to construct a new smart hydrogel coating with high binding to vascular stents that respond to ROS for drug release.…”

Improving the mechanical properties of 3D printed GelMA composite hydrogels by tannic acid

“…It has become an important scaffold material for 3D bio‐printed tissues and organs. Therefore, hydrogels have broad application prospects in many fields, 13 such as drug delivery systems, skin dressings, tissue repair, contact lenses, sustained‐release materials, preservatives, and thickeners 14–22 . Unfortunately, the hydrogels' three‐dimensional network topologies have a high water content, which makes their mechanical strength often inadequate.…”

“…Therefore, hydrogels have broad application prospects in many fields, 13 such as drug delivery systems, skin dressings, tissue repair, contact lenses, sustained-release materials, preservatives, and thickeners. [14][15][16][17][18][19][20][21][22] Unfortunately, the hydrogels' three-dimensional network topologies have a high water content, which makes their mechanical strength often inadequate. Although hydrogel has become an important scaffold material for 3D bioprinted tissues and organs, they still lack good mechanical properties compared with biological tissues such as blood vessels, muscles, and skin.…”

Development of nanoparticle‐based drug delivery system for inflammation treatment and diagnosis

“…Currently, therapeutic drugs for inflammation-related diseases include steroids, nonsteroids, 10 antileukotrienes, 11 pro-inflammatory cytokine inhibitors, 12 anti-inflammatory peptides, and small interfering RNAs (siRNA) drugs. 13,14 Despite various categories of therapeutic drugs, there remain some challenges for their clinical use. Existing drug defects include off-target side effects caused by nonspecific biodistribution, low bioavailability as well as short half-life.…”